In March 2024, the first over-the-counter (OTC) oral contraceptive in the United States – Opill – became available, which has the potential to increase contraceptive access. However, the $20 retail cost of Opill and challenges using insurance may be preventing many individuals from accessing it in retail settings. Instead, some may be accessing Opill from clinics, hospitals, or non-profit organizations that receive Opill donations and can provide Opill at no cost. There is no data on the experiences of individuals accessing Opill donations or on the experiences of organizations participating int the manufacturer’s bulk donation program. We – a collaboration of researchers, advocates, and staff at organizations distributing Opill – therefore propose a multi-methods study that will: 1.) quantitatively assess the effectiveness of distribution strategies employed by organizations participating in the bulk donation program; 2.) explore the experiences of organizations receiving Opill donations; and 3.) document the experiences of individuals accessing Opill donations. To achieve these aims, we will collect service delivery statistics from organizations that have participated in the bulk donation program, conduct in-depth interviews with staff at organizations distributing Opill donations, and host focus groups discussions with individuals who have accessed Opill donations. Study findings will assess the success of distribution strategies based on average monthly distribution rates, reveal the ways organizations track, store, and distribute Opill; and highlight how accessing Opill at no cost has influenced people’s reproductive lives, which may provide evidence for increasing the availability of no- or low-cost Opill beyond the bulk donation program.